Grünenthal’s largest manufacturing investment in the past three decades 

Grünenthal operates a robust production network with five manufacturing sites in Germany, Switzerland, Italy, Chile, and Ecuador. These sites produce medicines from Grünenthal's portfolio and offer contract manufacturing services to third parties. Recently, Grünenthal has invested over €80 million into enhancing its production capabilities in Latin America, the largest investment in manufacturing infrastructure in the company’s history. Implementing a standardized approach to product robustness, quality, and regulatory compliance across all its global manufacturing sites, the investment further strengthens production excellence. It contributes to expand the geographical footprint of Grünenthal’s Latin American facilities, ensuring a reliable supply of medicines for patients across Latin America, Europe, and beyond. 

Santiago de Chile

Grünenthal has been operating in Santiago de Chile for 45 years. In 2017, a 1,150-square-meter hormone plant was added to the campus, representing the company’s centre of excellence for hormone production and the most modern facility of its kind in Latin America. It delivers high-quality women’s health products to the Chilean market and also provides products for other Latin American markets, including Brazil and Mexico.

Now, a fully refurbished 3,500-square-meter facility will enable a production volume of up to 1.8 billion tablets annually. Featuring state-of-the-art technology, the Santiago campus strengthens Grünenthal’s position among the leading pharmaceutical companies in Chile, providing employees with a cutting-edge working environment with various opportunities for personal development. Grünenthal aims to complete the certification process with the European Medicines Agency (EMA) by November 2025, enabling the supply of medicines from Chile to Europe.

Quito

Grünenthal’s campus in Quito features Ecuador's largest and most modern manufacturing plant for solid, semi-solid, and liquid pharmaceuticals. It is Grünenthal’s central production facility, pharmaceutical development centre, and logistics hub in Latin America.

Our experts in Ecuador can manufacture a variety of formulations such as granules, coated tablets, capsules, liquids, semi-solids and packaging in various blister, sachet or bottle forms. Recognized as a preferred contract manufacturer throughout Latin America, our colleagues serve various multinational corporations. 

A new 1,800-square-metre plant will enable the production of up to 300 million high-quality tablets annually to serve pain patients across 17 European countries. It blends into the existing 50,000-square-meter facility. The plant north of Quito guarantees Grünenthal’s high-quality standards. It is certified by various Latin American authorities, such as ANVISA (Brazil) or INVIMA (Colombia). In addition, it is one of the few facilities in Latin America licensed to export to Europe and the only one in Ecuador with an EU Good Manufacturing Practice certificate.